Insulin Glargine Market Forecast Highlights Expanding Demand for Long-Acting Insulin Therapies Worldwide

The global Insulin Glargine Market size was valued at USD 1,330.8 million in 2023 and is projected to grow from USD 1,388.3 million in 2024 to USD 2,062.7 million by 2031, exhibiting a CAGR of 5.82% during the forecast period. The market is expanding due to the increasing prevalence of diabetes, growing demand for long-acting basal insulin therapies, improvements in insulin delivery formats, and increasing efforts to make insulin treatments more accessible and affordable. Insulin glargine is a long-acting insulin analog used to help maintain blood glucose control in people with diabetes, and the competitive landscape is evolving as branded therapies, biosimilars, and alternative insulin products expand treatment options. Biocon and Viatris, for instance, have commercialized insulin glargine biosimilar products in vial and pre-filled pen presentations, illustrating the growing role of biosimilars in expanding access to long-acting insulin therapy.

Get the Full Detailed Insights Report: https://www.kingsresearch.com/insulin-glargine-market-836 

Key Highlights of the Insulin Glargine Market

• 2023 Market Size: USD 1,330.8 Million

• 2024 Market Size: USD 1,388.3 Million

• 2031 Projected Market Size: USD 2,062.7 Million

• Forecast CAGR: 5.82% from 2024 to 2031

• Rising prevalence of diabetes is supporting demand for basal insulin therapies.

• Increasing adoption of long-acting insulin formulations is supporting market expansion.

• Biosimilar insulin glargine is creating greater competition and opportunities for improving affordability.

• Pre-filled delivery formats are gaining importance because of their convenience and ease of administration.

• Hospital pharmacies and retail pharmacies remain important distribution channels, while online sales are expanding.

• Type 2 diabetes represents a major application area because of the large and growing patient population.

• Leading companies are focusing on product innovation, manufacturing capabilities, affordability, and broader patient access.

Insulin Glargine Market Overview

Insulin glargine is a long-acting insulin analog primarily used as basal insulin therapy to help maintain blood glucose levels over an extended period. Its long duration of action has made it an important component of diabetes management for patients who require insulin therapy. The insulin glargine market encompasses different delivery formats and distribution channels designed to meet the needs of patients, healthcare professionals, hospitals, pharmacies, and other healthcare providers.

The market is being influenced by the increasing global burden of diabetes and the growing need for effective long-term disease management. Diabetes requires continuous monitoring and treatment, and insulin remains essential for many patients, particularly individuals with Type 1 diabetes and patients with Type 2 diabetes who require insulin therapy as their condition progresses. The increasing focus on glycemic control and prevention of diabetes-related complications is consequently supporting demand for reliable basal insulin therapies.

The competitive environment is also changing as biosimilar insulin glargine products become increasingly available. Biocon and Viatris have highlighted the availability of insulin glargine biosimilar products in both vial and pre-filled pen presentations, with their U.S. product receiving interchangeable biosimilar status. This development demonstrates the potential for biosimilars to increase competition and provide additional treatment options.

At the same time, manufacturers are focusing on improving patient convenience through pre-filled syringes and pen-based delivery systems. Ease of use is becoming increasingly important as healthcare systems seek to improve treatment adherence and simplify diabetes management.

The market is also influenced by healthcare reimbursement policies, regulatory approvals, pricing structures, supply chain considerations, and the increasing demand for affordable insulin. Consequently, manufacturers are adopting strategies that combine product development with geographic expansion, partnerships, biosimilar development, and improvements in manufacturing efficiency.

Growth Drivers of the Insulin Glargine Market

Increasing Prevalence of Diabetes

The rising prevalence of diabetes worldwide is one of the most significant factors driving the insulin glargine market. Diabetes is a chronic metabolic disorder requiring continuous disease management, and a substantial proportion of patients eventually require insulin therapy.

The increasing number of individuals living with Type 2 diabetes is particularly important to the market. While lifestyle modification and non-insulin medications can be effective for many patients, insulin therapy may become necessary when adequate glycemic control cannot be achieved through other approaches.

The growing diabetes burden is therefore creating a larger addressable patient population for insulin therapies, including long-acting insulin analogs such as insulin glargine.

Growing Demand for Long-Acting Basal Insulin

Insulin glargine provides long-acting basal insulin coverage and is widely incorporated into diabetes treatment regimens. Its role in maintaining relatively consistent basal insulin levels makes it an important therapeutic option for patients requiring insulin replacement or supplementation.

The continued need for convenient basal insulin therapy is expected to support market demand throughout the forecast period.

Increasing Availability of Biosimilar Insulin Glargine

The development of biosimilar insulin glargine products is transforming the competitive environment. Biosimilars can provide additional options for patients and healthcare systems and may create price competition with reference products.

Biocon reports that its insulin glargine biosimilar has been approved in multiple countries and that Biocon and Viatris launched interchangeable insulin glargine products in the U.S. The company describes the product as being available in both vial and pre-filled pen presentations.

Increasing biosimilar competition is expected to encourage manufacturers to focus on cost efficiency, market access, supply reliability, and product differentiation.

Growing Focus on Affordable Diabetes Treatment

The cost of diabetes treatment is an important consideration for patients, healthcare providers, insurers, and governments. Insulin affordability has therefore become a significant industry issue.

Biosimilar insulin products may contribute to increased treatment access by creating more competitive markets. Biocon has specifically positioned its insulin portfolio around improving affordability and accessibility, while its biosimilar insulin glargine portfolio has expanded across international markets.

Latest Market Trends

Increasing Adoption of Biosimilar Insulin Products

One of the most important trends in the insulin glargine market is the expansion of biosimilar products. As patents and market exclusivity periods for established biologic therapies expire, biosimilar manufacturers are increasingly entering the market.

The U.S. launch of interchangeable insulin glargine products by Biocon Biologics and Viatris represents an important development in this segment. The products were offered in branded and unbranded versions and in vial and pre-filled presentations.

The expansion of biosimilars is expected to increase competition and encourage manufacturers to offer cost-effective treatment alternatives.

Shift Toward Convenient Delivery Formats

Patient convenience is becoming an increasingly important consideration in insulin therapy. Pre-filled formats can simplify the preparation and administration process compared with conventional vial-and-syringe approaches.

Manufacturers are therefore increasingly focusing on convenient delivery systems that can support treatment adherence and improve the overall patient experience.

Expansion of Digital Diabetes Management

The insulin market is increasingly interacting with digital diabetes management technologies, including continuous glucose monitoring systems, connected insulin delivery devices, digital health platforms, and data-driven treatment management.

These technologies are supporting a more integrated approach to diabetes care, enabling patients and healthcare professionals to obtain more detailed information regarding glucose patterns and treatment responses.

Increasing Focus on Personalized Diabetes Care

Diabetes management is increasingly moving toward individualized treatment strategies based on patient characteristics, glucose levels, lifestyle, and treatment response.

Advances in glucose monitoring and digital health technologies are creating opportunities for more personalized insulin management. Research into algorithm-based insulin adjustment and data-driven approaches further reflects the industry's movement toward individualized diabetes care.

Insulin Glargine Market Segmentation Analysis

By Type

The insulin glargine market is segmented into Single Dose Vial and Pre-Filled Syringe.

Single Dose Vial

Single dose vials remain an important product format in the insulin glargine market. Vials can be utilized with conventional insulin syringes and are widely integrated into clinical and home-based diabetes management.

The segment continues to benefit from established prescribing practices and familiarity among healthcare professionals and patients. Vial-based administration can also provide flexibility in dosing under appropriate medical guidance.

However, manufacturers are increasingly competing with convenient delivery formats, which may influence future demand patterns.

Pre-Filled Syringe

The pre-filled syringe segment is expected to witness strong demand due to its convenience and ease of use. Pre-filled delivery formats can reduce preparation steps and may be particularly useful for patients seeking a simpler insulin administration routine.

Biocon and Viatris' insulin glargine products have been offered in vial and pre-filled pen presentations, highlighting the industry's increasing focus on convenient delivery formats.

As patient-centered care becomes increasingly important, manufacturers are expected to continue investing in convenient delivery technologies.

By Application

Type 2 Diabetes

Type 2 diabetes represents a major application segment within the insulin glargine market. The increasing prevalence of Type 2 diabetes worldwide is creating sustained demand for effective glucose-lowering therapies.

Insulin glargine may be used as basal insulin therapy when patients require insulin to achieve appropriate glycemic control. The increasing diabetes burden, aging populations, changing lifestyles, and growing awareness regarding diabetes management are expected to support demand.

The expansion of biosimilar insulin glargine may further support this segment by increasing the number of available therapeutic options.

Type 1 Diabetes

Type 1 diabetes is another important application area. Individuals with Type 1 diabetes require lifelong insulin replacement because the body produces little or no insulin.

Long-acting basal insulin can form an important component of insulin treatment regimens for these patients. Biocon's information regarding its insulin glargine biosimilar indicates use in adults and pediatric patients with Type 1 diabetes and adults with Type 2 diabetes in the U.S.

Growing awareness, improved diagnosis, and expanding access to diabetes care are expected to support the Type 1 diabetes segment.

By Distribution Channel

Hospital Pharmacy

Hospital pharmacies are a key distribution channel for insulin glargine, particularly where patients receive inpatient treatment, specialist consultations, or chronic disease management services.

Hospitals maintain structured procurement and distribution systems that ensure medications are available to patients requiring insulin therapy. The continued expansion of healthcare infrastructure and hospital-based diabetes services is expected to support this channel.

Online Sales

Online sales are emerging as an increasingly relevant channel for pharmaceutical products. The growth of digital healthcare platforms, online pharmacy services, electronic prescriptions, and home delivery is creating additional opportunities for insulin distribution.

Convenience is a key factor supporting online sales, particularly for patients managing chronic conditions that require regular medication refills.

However, insulin products require appropriate storage, handling, and distribution conditions. Therefore, online pharmaceutical providers must maintain suitable cold-chain and product-quality practices.

Retail Pharmacy

Retail pharmacies remain an important distribution channel due to their accessibility and broad geographic presence. Patients can obtain prescriptions and refill long-term diabetes medications through community pharmacies.

The availability of branded and biosimilar insulin products through pharmacy networks may also influence purchasing decisions and treatment accessibility.

Others

The "Others" segment includes additional healthcare distribution channels such as specialty pharmacies, clinics, institutional procurement, and other authorized pharmaceutical supply networks.

These channels can play a particularly important role in markets where insulin distribution is managed through specialized healthcare systems.

Regional Analysis

North America

North America represents a major market for insulin glargine due to the presence of advanced healthcare infrastructure, high diabetes treatment expenditure, established pharmaceutical companies, and strong demand for innovative diabetes therapies.

The United States is particularly important because of its large diabetes population and sophisticated pharmaceutical distribution system. The country has also witnessed important developments in biosimilar insulin glargine. Biocon and Viatris launched interchangeable insulin glargine products in the U.S., creating an additional competitive option alongside established insulin therapies.

The region is also characterized by strong competition among pharmaceutical companies and increasing attention to insulin affordability.

Europe

Europe is expected to maintain significant market demand due to well-developed healthcare systems, extensive diabetes treatment infrastructure, and increasing adoption of biosimilar medicines.

Regulatory frameworks supporting biosimilar competition can create opportunities for manufacturers offering insulin glargine alternatives. Biocon has reported approvals and commercialization of its insulin glargine biosimilar across European markets through its partnership with Mylan/Viatris.

Increasing healthcare expenditure and emphasis on cost-effective pharmaceutical procurement are expected to support the market.

Asia-Pacific

Asia-Pacific is expected to witness considerable growth during the forecast period. Rising diabetes prevalence, increasing healthcare expenditure, expanding pharmaceutical manufacturing capabilities, and improving access to modern therapies are contributing to market development.

Countries such as India, China, Japan, South Korea, and Australia represent important markets for insulin therapies.

India is particularly significant because of its expanding pharmaceutical manufacturing capabilities and growing demand for affordable diabetes treatment. Biocon has developed a strong insulin portfolio and has highlighted its insulin glargine activities across multiple international markets.

The growing availability of biosimilar products is expected to further support market development across Asia-Pacific.

Latin America

Latin America is expected to witness steady market growth due to increasing diabetes prevalence, improvements in healthcare infrastructure, and growing awareness of diabetes diagnosis and management.

The availability of affordable insulin products will remain an important factor influencing market penetration in the region. Manufacturers that can develop efficient distribution networks and competitive pricing strategies are likely to benefit from increasing demand.

Middle East & Africa

The Middle East & Africa region is projected to experience gradual market expansion as healthcare infrastructure improves and diabetes awareness increases.

Several countries in the region are facing a growing burden of diabetes, creating a need for accessible and reliable insulin therapies. Investments in hospitals, specialty care centers, pharmaceutical supply chains, and chronic disease management programs are expected to support market development.

Competitive Landscape

The global insulin glargine market is characterized by competition among multinational pharmaceutical companies, biotechnology firms, and manufacturers developing biosimilar insulin products.

The report includes solutions offered by companies such as Novo Nordisk AS, Sanofi Aventis, Biocon, Eli Lilly and Company, Julphar, Gan & Lee Pharmaceuticals USA Corp., Kalbe Pharma, Viatris Inc., WOCKHARDT, Boehringer Ingelheim International GmbH, and others.

Novo Nordisk AS

Novo Nordisk is a major global diabetes-focused pharmaceutical company with extensive expertise in insulin therapies and diabetes management. The company continues to invest in next-generation diabetes treatments and technologies.

Sanofi Aventis

Sanofi has historically maintained a strong position in long-acting insulin through its insulin glargine portfolio. Its established market presence, global distribution capabilities, and extensive diabetes-care experience contribute to its competitive position.

Biocon

Biocon is a major player in biosimilar insulin development and has established a strong position in affordable insulin therapies. The company reports that its insulin glargine biosimilar has been approved across numerous countries and has been commercialized through strategic partnerships.

Eli Lilly and Company

Eli Lilly maintains a strong presence in diabetes care and competes in the insulin market through a broad portfolio of diabetes therapies. Its continued investments in innovative insulin delivery and next-generation therapies contribute to competitive market dynamics.

Julphar

Julphar contributes to the pharmaceutical landscape in the Middle East and international markets, with its portfolio spanning multiple therapeutic areas.

Gan & Lee Pharmaceuticals USA Corp.

Gan & Lee Pharmaceuticals is involved in diabetes-focused pharmaceutical development and insulin products, contributing to increasing competition within the global insulin market.

Kalbe Pharma

Kalbe Pharma participates in the pharmaceutical sector with a presence in diabetes care and other therapeutic categories, supporting the development and distribution of healthcare products across its markets.

Viatris Inc.

Viatris is an important participant in the biosimilar insulin segment. In partnership with Biocon Biologics, the company launched insulin glargine-yfgn products in the U.S., including an interchangeable biosimilar insulin glargine.

WOCKHARDT

WOCKHARDT is a pharmaceutical company with a presence across several international markets and contributes to the competitive pharmaceutical landscape through its broad healthcare portfolio.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim is a global pharmaceutical company with expertise across multiple therapeutic areas. Its participation in the broader diabetes pharmaceutical landscape contributes to the competitive environment surrounding innovative diabetes treatment.

Strategic Developments and Market Opportunities

The insulin glargine market offers significant opportunities for companies capable of balancing innovation, affordability, regulatory compliance, and reliable supply.

Expansion of Biosimilar Portfolios

The continued development of biosimilar insulin glargine represents one of the most significant opportunities in the market. Biosimilar manufacturers can potentially improve access by offering competitive alternatives to established products.

Interchangeability can further increase the commercial potential of eligible biosimilars. Biocon's insulin glargine product received U.S. interchangeable biosimilar status, demonstrating the importance of regulatory milestones in the development of competitive insulin markets.

Emerging Markets Offer Growth Opportunities

Developing economies represent significant opportunities due to growing diabetes prevalence and improving access to healthcare. Companies with local manufacturing capabilities, affordable products, and strong distribution networks can strengthen their presence in these markets.

Product Convenience and Patient-Centric Design

Future competition will increasingly focus on improving patient experience. Pre-filled delivery formats, simplified administration systems, and connected diabetes management technologies can support treatment adherence and convenience.

Challenges Facing the Insulin Glargine Market

Despite positive growth prospects, the market faces several challenges.

Pricing and Affordability Pressure

Insulin affordability remains a major issue in many healthcare systems. Manufacturers face pressure to reduce prices while maintaining product quality, research investment, manufacturing standards, and supply reliability.

Regulatory Complexity

Insulin products are biologic therapies and require extensive regulatory evaluation. Biosimilar manufacturers must demonstrate appropriate similarity and meet stringent quality and safety requirements.

Cold-Chain and Supply Requirements

Insulin products require controlled storage and transportation conditions. Maintaining appropriate supply-chain infrastructure can be challenging in emerging markets and remote areas.

Competition from Alternative Diabetes Therapies

The diabetes treatment landscape is changing rapidly, with increasing use of non-insulin therapies and new approaches to glucose management. Eli Lilly and Novo Nordisk, for example, have also been advancing longer-acting insulin concepts, illustrating how treatment innovation may influence future competition.

These developments do not eliminate the need for insulin glargine but increase pressure on manufacturers to demonstrate clinical, economic, and convenience advantages.

Future Outlook

The global insulin glargine market is expected to maintain a positive growth trajectory through 2031, supported by the rising burden of diabetes, increasing demand for basal insulin therapies, expanding access to healthcare, and growing adoption of biosimilar products.

The market's projected expansion from USD 1,388.3 million in 2024 to USD 2,062.7 million by 2031 reflects sustained demand for long-acting insulin treatment.

Biosimilars are expected to remain a central theme in the market's development. The increasing availability of insulin glargine biosimilars may encourage price competition, expand treatment choices, and support broader access to insulin therapy. Biocon's experience with insulin glargine commercialization and its collaboration with Viatris demonstrate the role of strategic partnerships in expanding biosimilar access.

Pre-filled delivery formats are also likely to gain importance as patients and healthcare providers increasingly prioritize convenience and ease of administration. Manufacturers that combine reliable drug delivery with patient-friendly designs may gain stronger market positions.

In addition, digital diabetes management will increasingly complement insulin treatment. Continuous glucose monitoring, connected devices, data analytics, and personalized treatment strategies could enable more informed diabetes management and improve the overall patient experience.

From a regional perspective, North America and Europe are expected to remain important markets due to advanced healthcare systems and established pharmaceutical infrastructure, while Asia-Pacific is likely to provide significant growth opportunities due to its large patient population, expanding healthcare expenditure, and increasing pharmaceutical manufacturing capabilities.

Overall, the insulin glargine market is expected to evolve toward a more competitive, accessible, and patient-centered environment. Pharmaceutical companies that successfully combine clinical quality, affordability, convenient delivery, manufacturing efficiency, biosimilar development, and global distribution capabilities are likely to be well positioned to benefit from market opportunities through 2031.

Conclusion

The Insulin Glargine Market is positioned for steady growth as diabetes continues to create substantial healthcare demand worldwide. With the market projected to reach USD 2,062.7 million by 2031, the industry is expected to benefit from increasing insulin requirements, greater awareness of diabetes management, technological advances in delivery systems, and the expanding presence of biosimilar therapies.

The competitive environment is likely to become increasingly dynamic as established pharmaceutical companies and biosimilar manufacturers compete on affordability, accessibility, innovation, and product convenience. The continued development of pre-filled delivery formats and the expansion of biosimilar insulin glargine are expected to remain important market trends.

As healthcare systems increasingly prioritize value-based care and wider access to essential medicines, insulin glargine manufacturers will have opportunities to expand into emerging markets while improving treatment affordability. With continued innovation and investment across the pharmaceutical value chain, the market is expected to remain an important segment of the global diabetes therapeutics industry through the forecast period.

About Kings Research

Kings Research is a leading market research and consulting firm that provides comprehensive market intelligence and strategic insights to businesses across various industries. The company offers syndicated reports, customized research, consulting services, and strategic advisory solutions designed to help organizations understand evolving market dynamics, identify growth opportunities, and make informed business decisions.